106 related articles for article (PubMed ID: 12737118)
1. Antiretroviral therapy in the treatment-experienced patient.
Gallant JE
AIDS Read; 1999 Jul; 9(4):284-91. PubMed ID: 12737118
[TBL] [Abstract][Full Text] [Related]
2. Assessing resistance costs of antiretroviral therapies via measures of future drug options.
Jiang H; Deeks SG; Kuritzkes DR; Lallemant M; Katzenstein D; Albrecht M; DeGruttola V
J Infect Dis; 2003 Oct; 188(7):1001-8. PubMed ID: 14513420
[TBL] [Abstract][Full Text] [Related]
3. Boosted protease inhibitor-based or nonnucleoside reverse transcriptase-based HAART: is there a best choice for antiretroviral-naive HIV-1 infected patients?
Cuzin L; Allavena C; Morlat P; Dellamonica P
AIDS Rev; 2008; 10(4):205-11. PubMed ID: 19092976
[TBL] [Abstract][Full Text] [Related]
4. Bridging the gap. Bringing new antiretroviral medications into the clinic.
Williams A
Adv Nurse Pract; 1999 Jan; 7(1):24-30; quiz 31-2. PubMed ID: 10030167
[TBL] [Abstract][Full Text] [Related]
5. Initiation of antiretroviral therapy: implications of recent findings.
Saag MS
Top HIV Med; 2004; 12(3):83-8. PubMed ID: 15310939
[TBL] [Abstract][Full Text] [Related]
6. Antiretroviral resistance among HIV-infected persons who have died in British Columbia, in the era of modern antiretroviral therapy.
Recsky MA; Brumme ZL; Chan KJ; Wynhoven B; Yip B; Dong WW; Heath KV; Montaner JS; Levy AR; Hogg RS; Harrigan PR
J Infect Dis; 2004 Jul; 190(2):285-92. PubMed ID: 15216463
[TBL] [Abstract][Full Text] [Related]
7. Individualized therapy for the treatment-experienced patient.
Walmsley S
AIDS Read; 2003 Jun; 13(6 Suppl):S11-5. PubMed ID: 12838742
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and risk factors associated with antiretroviral resistance in HIV-1-infected children.
Delaugerre C; Warszawski J; Chaix ML; Veber F; Macassa E; Buseyne F; Rouzioux C; Blanche S
J Med Virol; 2007 Sep; 79(9):1261-9. PubMed ID: 17607781
[TBL] [Abstract][Full Text] [Related]
9. Essential benefits of nucleoside analogue regimens in failing therapy.
Geretti AM
J HIV Ther; 2004 May; 9(2):28-33. PubMed ID: 15238873
[TBL] [Abstract][Full Text] [Related]
10. Drug resistance genotypes predict response to amprenavir-containing regimens in highly drug-experienced HIV-1-infected patients.
Sabin CA; Wilkins E; Murphy M; Fisher M; de Ruiter A; Easterbrook PJ; Leen C; Vlahakis E; Cane PA; Li X; Pillay D;
Antivir Ther; 2003 Aug; 8(4):301-8. PubMed ID: 14518699
[TBL] [Abstract][Full Text] [Related]
11. Nucleoside and nucleotide analogue reverse transcriptase inhibitors: a clinical review of antiretroviral resistance.
Gallant JE; Gerondelis PZ; Wainberg MA; Shulman NS; Haubrich RH; St Clair M; Lanier ER; Hellmann NS; Richman DD
Antivir Ther; 2003 Dec; 8(6):489-506. PubMed ID: 14760883
[TBL] [Abstract][Full Text] [Related]
12. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
[TBL] [Abstract][Full Text] [Related]
13. Antiretroviral therapy in AIDS patients with tuberculosis.
Moreno S; Hernández B; Dronda F
AIDS Rev; 2006; 8(3):115-24. PubMed ID: 17078482
[TBL] [Abstract][Full Text] [Related]
14. Resistance profiles and adherence at primary virological failure in three different highly active antiretroviral therapy regimens: analysis of failure rates in a randomized study.
Røge BT; Barfod TS; Kirk O; Katzenstein TL; Obel N; Nielsen H; Pedersen C; Mathiesen LR; Lundgren JD; Gerstoft J
HIV Med; 2004 Sep; 5(5):344-51. PubMed ID: 15369509
[TBL] [Abstract][Full Text] [Related]
15. What's new in the fight against AIDS.
Godwin C
RN; 2004 Apr; 67(4):46-52; quiz 53. PubMed ID: 15132046
[No Abstract] [Full Text] [Related]
16. Drug-class-wide resistance to antiretrovirals in HIV-infected patients failing therapy: prevalence, risk factors and virological outcome.
Tozzi V; Zaccarelli M; Bonfigli S; Lorenzini P; Liuzzi G; Trotta MP; Forbici F; Gori C; Bertoli A; Bellagamba R; Narciso P; Perno CF; Antinori A;
Antivir Ther; 2006; 11(5):553-60. PubMed ID: 16964822
[TBL] [Abstract][Full Text] [Related]
17. Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis.
Sungkanuparph S; Overton ET; Seyfried W; Groger RK; Fraser VJ; Powderly WG
Clin Infect Dis; 2005 Nov; 41(9):1326-32. PubMed ID: 16206110
[TBL] [Abstract][Full Text] [Related]
18. Designing anti-AIDS drugs targeting the major mechanism of HIV-1 RT resistance to nucleoside analog drugs.
Sarafianos SG; Hughes SH; Arnold E
Int J Biochem Cell Biol; 2004 Sep; 36(9):1706-15. PubMed ID: 15183339
[TBL] [Abstract][Full Text] [Related]
19. Therapy of HIV infection.
Chang YC; Tyring SK
Dermatol Ther; 2004; 17(6):449-64. PubMed ID: 15571495
[TBL] [Abstract][Full Text] [Related]
20. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
